| ||||||||||||||
|
|
|||||||||||||



Department of *Cardiothoracic and Vascular Anesthesia & Intensive Care Medicine and
Cardiothoracic Surgery, University of Vienna, Vienna, Austria;
Department of Biostatistics, Harvard Medical School, Boston, Massachusetts
Address and correspondence and reprint requests to Edda M. Tschernko, MD, Department of Cardiothoracic Anesthesia & Intensive Care Medicine, Vienna General Hospital, University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria. Address e-mail to edda.tschernko{at}univie.ac.at
Optimal analgesia is important after thoracotomy in pulmonary-limited patients to avoid pain-related pulmonary complications. Thoracic epidural anesthesia (TEA) can provide excellent pain relief. However, potential paralysis of respiratory muscles and changes in bronchial tone might be unfavorable in patients with end-stage chronic obstructive pulmonary disease (COPD). Therefore, we evaluated the effect of TEA on maximal inspiratory pressure, pattern of breathing, ventilatory mechanics, and gas exchange in 12 end-stage COPD patients. Pulmonary resistance, work of breathing, dynamic intrinsic positive end-expiratory pressure, and peak inspiratory and expiratory flow rates were evaluated by assessing esophageal pressure and airflow. An increase in minute ventilation (7.50 ± 2.60 vs 8.70 ± 2.10 L/min; P = 0.04) by means of increased tidal volume (0.46 ± 0.16 vs 0.53 ± 0.14 L/breath; P = 0.003) was detected after TEA. These changes were accompanied by an increase in peak inspiratory flow rate (0.48 ± 0.17 vs 0.55 ± 0.14 L/s; P = 0.02) and a decrease in pulmonary resistance (20.7 ± 9.9 vs 16.6 ± 8.1 cm H2O · L-1 · s-1; P = 0.02). Peak expiratory flow rate, dynamic intrinsic positive end-expiratory pressure, work of breathing, PaO2, and maximal inspiratory pressure were unchanged (all P > 0.50). We conclude that TEA with bupivacaine 0.25% can be used safely in end-stage COPD patients.
Implications: Thoracic epidural anesthesia with bupivacaine 0.25% does not impair ventilatory mechanics and inspiratory respiratory muscle strength in severely limited chronic obstructive pulmonary disease patients. Thus, thoracic epidural anesthesia can be used safely in patients with end-stage chronic obstructive pulmonary disease.
This article has been cited by other articles:
![]() |
S. S. Liu and C. L. Wu Effect of Postoperative Analgesia on Major Postoperative Complications: A Systematic Update of the Evidence Anesth. Analg., March 1, 2007; 104(3): 689 - 702. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Licker, I. Widikker, J. Robert, J.-G. Frey, A. Spiliopoulos, C. Ellenberger, A. Schweizer, and J.-M. Tschopp Operative mortality and respiratory complications after lung resection for cancer: impact of chronic obstructive pulmonary disease and time trends. Ann. Thorac. Surg., May 1, 2006; 81(5): 1830 - 1837. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Macias, P. Monedero, M. Adame, W. Torre, I. Fidalgo, and F. Hidalgo A Randomized, Double-Blinded Comparison of Thoracic Epidural Ropivacaine, Ropivacaine/Fentanyl, or Bupivacaine/Fentanyl for Postthoracotomy Analgesia Anesth. Analg., November 1, 2002; 95(5): 1344 - 1350. [Abstract] [Full Text] [PDF] |
||||
|